In this article, we will look at the 12 Most Profitable Blue Chip Stocks to Invest In Now.

On March 12, Stephen Parker, JPMorgan Private Bank co-head of global investment strategy, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and the effects of the Iran war. He stated that he has consistently maintained that geopolitical events rarely have long-lasting impacts on markets. However, at the same time, it is important to recognise that they do have the potential to cause short-term disruptions, especially if energy markets are at the center of the storm, as they are right now.

READ ALSO: 15 Best Penny Stocks to Buy According to Reddit AND 12 Best Stocks That Will Always Grow.

He summarized the three primary things he is saying to clients, the first of which is staying diversified and disciplined, as diversification is back in vogue, and it continues to work. Secondly, he urged investors to think about looking for opportunities amidst volatility; option strategies that can give one some downside protection. The third point was to start building your shopping list, because to the extent we have seen more volatility in the near term, there are going to be really interesting fundamental stories that one is going to want to begin to phase into in portfolios.

Parker was also of the view that the market is currently pricing in a short-lived oil shock, with little medium-term impact anticipated. Recent oil price spikes suggest expectations for a pullback instead of a protracted disruption.

With these trends in view, let’s look at the most profitable blue-chip stocks to invest in now.

Our Methodology

We used stock screeners and holdings of blue-chip ETFs to make a list of profitable blue-chip stocks with the highest TTM net income and net income margins. We then picked 12 stocks with the highest number of hedge fund holders, as of Q3 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.

Note: All data was recorded on March 12.

​Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

12 Most Profitable Blue Chip Stocks to Invest In Now

12. AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price target on AstraZeneca PLC (NASDAQ:AZN) to 16,000 GBp from 15,500 GBp on March 10, reiterating a Buy rating on the shares and telling investors that it is updating its model after the company’s fiscal 2025 results and follow-up presentations at several investor conferences.

The rating update came after the company announced on March 9 that AstraZeneca PLC (NASDAQ:AZN) and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu has been accepted and granted Priority Review in the US by the Food and Drug Administration (FDA) for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.

It reported that the FDA grants Priority Review to applications for medicines that, upon their approval, have the potential to offer considerable improvements over the available treatment options by exhibiting safety or efficacy improvements, boosting patient compliance, or preventing serious conditions. AstraZeneca PLC (NASDAQ:AZN) stated that the Prescription Drug User Fee Act date, the FDA action date for its regulatory decision, is expected during the third quarter of 2026.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.

11. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) is one of the most profitable blue chip stocks to invest in now. On March 11, Citi lifted the price target on Johnson & Johnson (NYSE:JNJ) to $274 from $250 while maintaining a Buy rating on the shares. The firm told investors in a research note that it adjusted price targets in the medical technology group after the release of the fiscal Q4 reports, adding that despite the recent volatility, sector fundamentals remain “healthy”. Citi also stated that its top picks are iRhythm and Medtronic.

In a separate development, Johnson & Johnson (NYSE:JNJ) announced on March 10 the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication extension of TECVAYLI® as monotherapy to treat adult patients with relapsed/refractory multiple myeloma who have received at least one prior therapy.

Johnson & Johnson (NYSE:JNJ) further reported that the data from the Phase 3 MajesTEC-9 trial support the submission, which evaluates the safety and efficacy of teclistamab compared to the standard of care of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in 614 patients with RRMM.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, including oncology, infectious diseases, immunology, cardiovascular and metabolic diseases, and others. The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.